# DMTF1

## Overview
The DMTF1 gene encodes the cyclin D binding myb-like transcription factor 1, a crucial nuclear protein involved in cell cycle regulation and tumor suppression. As a transcription factor, DMTF1 plays a pivotal role in modulating the expression of genes associated with cell cycle checkpoints and apoptosis, particularly through its interactions with cyclin D and the ARF promoter. The protein is characterized by its myb-like DNA-binding domain and transactivation domains, which facilitate its regulatory functions. DMTF1 is subject to alternative splicing, resulting in multiple isoforms, each with distinct roles in cellular processes. The primary isoform, DMTF1α, is recognized for its tumor suppressive properties, while the shorter isoforms, DMTF1β and DMTF1γ, are associated with oncogenic activities. These isoforms interact with each other, influencing the overall function of DMTF1 in cancer biology. Alterations in DMTF1 expression and function have been implicated in various cancers, highlighting its significance as a potential therapeutic target (Li2020Mechanisms; Tian2017From).

## Structure
The DMTF1 protein is composed of 760 amino acids and includes several key structural domains. Its primary structure features a middle DNA-binding domain and two acidic transactivation domains located at the N- and C-terminals (Tian2017From). The DNA-binding domain, spanning amino acids 125-417, contains three myb-like repeats, which are crucial for its function as a transcription factor (Tian2017From). The predicted molecular weight of DMTF1 is 84.5 kDa, but it migrates at approximately 125-130 kDa in SDS-PAGE analyses, suggesting the presence of post-translational modifications or a unique structure (Tian2017From). DMTF1 is known to be phosphorylated by CDK4 and CDK6 in the presence of CCND1, which may regulate its activity (Tian2017From).

DMTF1 undergoes alternative splicing, resulting in multiple isoforms with distinct structural properties. The primary isoforms are DMTF1α, DMTF1β, and DMTF1γ. DMTF1α is the longest isoform, retaining the full DNA-binding ability due to its complete myb-homology region (Li2020Mechanisms; Tian2017From). In contrast, DMTF1β and DMTF1γ are shorter, lacking most of the myb-homology region and, consequently, the DNA-binding ability (Li2020Mechanisms). These isoforms result from alternative splicing events involving intron retention between exons 9 and 10 (Tian2017From).

## Function
The DMTF1 gene encodes a transcription factor that plays a significant role in cell cycle regulation and tumor suppression. It is involved in the regulation of multiple signaling pathways, including the CDKN2A-TP53 and MDM2-TP53 pathways, which are crucial for maintaining cellular homeostasis and preventing uncontrolled cell proliferation (Tian2017From). DMTF1 functions by inhibiting MDM2's E3 ubiquitin ligase activity, potentially increasing TP53 expression and causing cell cycle arrest (Tian2017From). This gene is also involved in the RAS-RAF signaling pathway, where its absence can lead to resistance to RAF-mediated premature senescence and susceptibility to RAS-induced transformation (Tian2017From).

DMTF1 is a haplo-insufficient tumor suppressor, meaning that a single functional copy of the gene is not sufficient to maintain normal function, which can lead to increased tumor formation (Li2020Mechanisms). The gene undergoes alternative splicing, resulting in three major isoforms: α, β, and γ, each with distinct functions. DMTF1α is known for its tumor suppressive role, while DMTF1β and γ have been associated with oncogenic properties (Li2020Mechanisms). DMTF1 is active in the nucleus, where it interacts with cyclin D to influence the progression of the cell cycle, particularly the G1/S transition (Tian2017From).

## Clinical Significance
Alterations in the DMTF1 gene, including mutations and changes in expression levels, have been implicated in various cancers. In breast cancer, the DMTF1 gene undergoes alternative splicing, resulting in different isoforms with distinct roles. The DMTF1α isoform is associated with tumor suppressive functions, while DMTF1β and γ are linked to oncogenic activities. Increased expression of DMTF1β and γ, particularly in relation to DMTF1α, is associated with poor prognosis in breast cancer patients (Li2020Mechanisms; Tian2017From). DMTF1β is notably overexpressed in breast cancer, promoting cell proliferation and tumor development, and is linked to poor clinical outcomes (Tian2017From).

In colorectal cancer, miR-675-3p targets DMTF1, reducing its expression and promoting cancer cell growth. This interaction highlights the role of DMTF1 as a tumor suppressor in colorectal cancer, where its downregulation is associated with increased cell proliferation (Yang2018miR‑675). In renal cell carcinoma, miR-6838-5p inhibits DMTF1 expression, affecting the ARF-p53 pathway and promoting cancer progression (Zhai2020MiR68385p). These findings underscore the significance of DMTF1 in cancer development and its potential as a therapeutic target.

## Interactions
The DMTF1 gene encodes three isoforms: DMTF1α, DMTF1β, and DMTF1γ, which participate in various interactions with proteins and nucleic acids. DMTF1α is known to physically associate with DMTF1β and DMTF1γ, forming complexes that influence its function. These interactions are significant in the context of breast cancer, where DMTF1β and DMTF1γ can enhance oncogenic processes by antagonizing the tumor-suppressive activities of DMTF1α (Li2020Mechanisms).

DMTF1α binds to D-type cyclins (D1, D2, and D3) and plays a role in cell cycle regulation by blocking S phase entry. It also binds to specific DNA sequences, such as the ARF promoter, to promote gene expression. DMTF1β and DMTF1γ, despite sharing some domains with DMTF1α, lack the full myb-homology region, which reduces their DNA binding affinity. These isoforms can associate with DMTF1α and interfere with its ability to transactivate the ARF promoter, thus modulating its tumor suppressive functions (Li2020Mechanisms).

The interactions between these isoforms are further characterized by their differential stability and degradation, with DMTF1β and DMTF1γ having shorter half-lives, potentially due to nonsense-mediated decay mechanisms (Li2020Mechanisms).


## References


[1. (Li2020Mechanisms) Jialiang Li, Ke Shi, Tianqi Xu, Jingru Hu, Tianxin Li, Guangyue Li, Kuida Chen, Dangdang Li, Kazushi Inoue, and Guangchao Sui. Mechanisms regulating dmtf1β/γ expression and their functional interplay with dmtf1α. International Journal of Oncology, 58(1):20–32, November 2020. URL: http://dx.doi.org/10.3892/ijo.2020.5146, doi:10.3892/ijo.2020.5146. This article has 1 citations and is from a peer-reviewed journal.](https://doi.org/10.3892/ijo.2020.5146)

[2. (Yang2018miR‑675) Xueliang Yang, Yang Lou, Minghua Wang, Chunlei Liu, Yanbo Liu, and Weili Huang. Mir‑675 promotes colorectal cancer cell growth dependent on tumor suppressor dmtf1. Molecular Medicine Reports, December 2018. URL: http://dx.doi.org/10.3892/mmr.2018.9780, doi:10.3892/mmr.2018.9780. This article has 3 citations and is from a peer-reviewed journal.](https://doi.org/10.3892/mmr.2018.9780)

3. (Zhai2020MiR68385p) MiR-6838-5p enhances the growth and invasion of renal cell carcinoma dependent on DMTF1 via inhibiting the ARF-p53 pathway. This article has 0 citations.

[4. (Tian2017From) Na Tian, Jialiang Li, Jinming Shi, and Guangchao Sui. From general aberrant alternative splicing in cancers and its therapeutic application to the discovery of an oncogenic dmtf1 isoform. International Journal of Molecular Sciences, 18(3):191, March 2017. URL: http://dx.doi.org/10.3390/ijms18030191, doi:10.3390/ijms18030191. This article has 13 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/ijms18030191)